FibroBiologics Inc. (NASDAQ: FBLG) announced the completion of a public offering that raised approximately $3 million in gross proceeds. The Houston-based biotechnology company sold 2,272,728 shares of common stock and accompanying warrants at $1.32 per share.

The warrants allow holders to purchase up to 2,272,728 additional shares at an exercise price of $1.32 per share. The warrants become exercisable upon stockholder approval and expire five years after that approval date. If fully exercised, the warrants could generate an additional $3 million for the company.

H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The Securities and Exchange Commission declared the registration statement effective on March 31, 2026.

FibroBiologics stated it plans to use the net proceeds for working capital and general corporate purposes. The company focuses on developing treatments for chronic diseases using fibroblast cells and fibroblast-derived materials.

The biotechnology company holds more than 270 issued and pending patents across clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer research.

The offering was conducted under a registration statement on Form S-1, and securities were offered through a prospectus available on the SEC's website.